It has been reported that inhibiting PFKP can downregulate BNP expression and protein synthesis during myocardial hypertrophy, thereby alleviating cardiac remodeling (Vigil Garcia et al., 2021; Wu et al., 2024). The gene discussed is NPPB; the disease is cardiac hypertrophy.